<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034771</url>
  </required_header>
  <id_info>
    <org_study_id>sedation in TBI</org_study_id>
    <nct_id>NCT04034771</nct_id>
  </id_info>
  <brief_title>The Effect of Melatonin Administration on Sedation Level as Adjuvant to Propofol</brief_title>
  <official_title>The Effect of Melatonin Administration on Sedation Level as Adjuvant to Propofol in Mechanically Ventilated Traumatic Brain Injury Patient: RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assess the effect of administration of exogenous melatonin as adjuvant to propofol
      on the level of sedation and consequently the rate of propofol infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      38 patients with traumatic brain injuries requiring mechanical ventilation and sedation were
      randomly allocated to two groups (melatonin group)19 patients and (control group)19 patients.
      In both groups a bolus of propofol 1mglkg was given by titration till the patient reached a
      sedation level value of (60-70) on the bispectral index (BIS), Then propofol infusion started
      at a rate of 1mglkglhr as a maintenance and rate adjusted according to our targeted sedation
      level, melatonin 10 mg tablet was crushed and mixed with 20 ml of water and administrated
      through a nasogastric tube followed by another 20 ml to flush out the residue for (melatonin
      group). While (control Group) received a placebo tablets by the same wayBIS value and
      propofol infusion rate was recorded over 12 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">April 5, 2018</completion_date>
  <primary_completion_date type="Actual">April 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>patient will be under general sedation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>level of sedation</measure>
    <time_frame>6 hours</time_frame>
    <description>observe the effect of the oral administration of 10 mg melatonin on decreasing the dose of propofol infusion in a mechanically ventilated patient with a traumatic brain injury using bispectral index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>â€¢ Arterial blood pressure</measure>
    <time_frame>6 hours</time_frame>
    <description>measuring Blood pressure in mmgh just before and after start of propofol infusion and every hour for successive 6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Measuring the heart rate as beats per minutes just before and after propofol infusion and every hour for the next 6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>TBI (Traumatic Brain Injury)</condition>
  <arm_group>
    <arm_group_label>propofol and melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>propofol iv infusion and melatonin 10 mg tablet through a nasogastric tube, once at admission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol iv infusion and a placebo tablets through a nasogastric tube once at admission</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 10 MG Oral Tablet</intervention_name>
    <description>Melatonin tablets</description>
    <arm_group_label>propofol and melatonin</arm_group_label>
    <other_name>circadian</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>propofol amp</description>
    <arm_group_label>propofol and melatonin</arm_group_label>
    <arm_group_label>propofol and placebo</arm_group_label>
    <other_name>diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>sugar pill manufactured to mimic melatonin tablets</description>
    <arm_group_label>propofol and placebo</arm_group_label>
    <other_name>palacebo tabletes (for melatonin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age group from 18 to 65

          -  Both sexes

          -  Patients on a mechanical ventilation and need sedation

          -  Patients who are vitally stable

        Exclusion Criteria:

          -  Gastro intestinal tract impractabililty

          -  Pregnant female

          -  Vitally unstable patients who cannot tolerate propofol infusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud s Soliman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasr Alini Univeristy Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Giza</state>
        <zip>11451</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Samarkandi A, Naguib M, Riad W, Thalaj A, Alotibi W, Aldammas F, Albassam A. Melatonin vs. midazolam premedication in children: a double-blind, placebo-controlled study. Eur J Anaesthesiol. 2005 Mar;22(3):189-96.</citation>
    <PMID>15852991</PMID>
  </reference>
  <reference>
    <citation>Yousaf F, Seet E, Venkatraghavan L, Abrishami A, Chung F. Efficacy and safety of melatonin as an anxiolytic and analgesic in the perioperative period: a qualitative systematic review of randomized trials. Anesthesiology. 2010 Oct;113(4):968-76. doi: 10.1097/ALN.0b013e3181e7d626. Review.</citation>
    <PMID>20823763</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>mahmoud salem soliman</investigator_full_name>
    <investigator_title>dr</investigator_title>
  </responsible_party>
  <keyword>melatonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified participant data for primary and secondary outcome measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>one month</ipd_time_frame>
    <ipd_access_criteria>open</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

